<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231828</url>
  </required_header>
  <id_info>
    <org_study_id>A90591-34</org_study_id>
    <nct_id>NCT01231828</nct_id>
  </id_info>
  <brief_title>Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.</brief_title>
  <acronym>AutoSop-Foie</acronym>
  <official_title>Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. Impact of Lactulose and Carnitine Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project will improve scientific knowledge regarding a recent law applying potentially to&#xD;
      every french driver. It will give for the first time an indication on the impact of alerting&#xD;
      treatments on driving risks. It will reinforce the links between different research&#xD;
      environments (sleep physiopathology, clinical research, cognitive neurosciences, drivers&#xD;
      supervision, virtual reality, pharmacology) among the &quot;RÃ©seau Eveil Sommeil Attention et&#xD;
      Transports&quot; (RESAT) network.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Excessive daytime sleepiness is responsible of 20% of traffic accidents and 2/3 of truck&#xD;
      accidents on French Freeways. Since the publication of a new law (2005 december 28th -&#xD;
      Official Journal) regulating fitness to drive, the Maintenance of Wakefulness Test (MWT) is&#xD;
      now mandatory to evaluate driving skills of patients suffering of excessive daytime&#xD;
      sleepiness. The MWT has shown a good predictability of driving handicap on simulators in&#xD;
      patients suffering from obstructive sleep apnea syndrome. Nevertheless no study has proven&#xD;
      yet the predictability of the MWT regarding real and simulated driving in patients suffering&#xD;
      from hepatic encephalopathy. Furthermore, even if therapeutic drugs significantly improve MWT&#xD;
      scores there is no data available concerning the impact of these drugs on fitness to drive.&#xD;
      Lactulose, a treatment of hepatic encephalopathy, has not been tested as a counter measure to&#xD;
      driving impairment. This lack of knowledge is a major handicap to evaluate driving skills of&#xD;
      treated patients suffering from excessive daytime sleepiness. The main objective of our&#xD;
      project is to test the predictive value of the MWT on real and simulated driving performances&#xD;
      in untreated and treated sleepy patients suffering from hepatic encephalopathy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep latency during Maintenance of Wakefulness Test (MWT)</measure>
    <time_frame>40 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nocturnal sleep quality and quantity will be measured by Polysomnography (PSG).</measure>
    <time_frame>1 night</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal sleep quality and quantity measured by Actimetry.</measure>
    <time_frame>during 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Versus placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Versus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <description>L-carnitine 4g per day (4 bottles of 10ml).</description>
    <arm_group_label>Carnitine</arm_group_label>
    <other_name>Levocarnil.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Lactulose (30-60 ml per day)</description>
    <arm_group_label>Lactulose</arm_group_label>
    <other_name>Duphalac.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis proved by histologic or clinico-biologics criteria, whatever its severity,&#xD;
             its stability defined by a child stable score (variation &lt; 2 points for the last&#xD;
             month) without any other disease which could be responsible of excessive daytime&#xD;
             sleepiness&#xD;
&#xD;
          -  driver's licence since at least 2 years&#xD;
&#xD;
          -  driving more than 2000 Km/year&#xD;
&#xD;
          -  registered to French national health and pensions organization&#xD;
&#xD;
          -  having given their written light agreement in order to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Night workers&#xD;
&#xD;
          -  neurologic disease&#xD;
&#xD;
          -  recent strong complication (&lt; 30 days)&#xD;
&#xD;
          -  recent antibiotics or lactulose intake&#xD;
&#xD;
          -  substance abusers (alcohol)&#xD;
&#xD;
          -  hepatoma more than 5 cm&#xD;
&#xD;
          -  disorder associated which engaged life prognostic in a short time&#xD;
&#xD;
          -  glycemia fasted &gt; 8 mmol/l&#xD;
&#xD;
          -  haemoglobin &lt; 10g/l&#xD;
&#xD;
          -  neurologic or psychiatric disorders associated which affect superiors functions,&#xD;
&#xD;
          -  hepatic encephalopathy stage 3 or 4&#xD;
&#xD;
          -  having participated in a clinical study during the last 6 months&#xD;
&#xD;
          -  drugs abusers&#xD;
&#xD;
          -  unable to drive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Astrid PIQUET</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thong DAO</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>February 26, 2013</last_update_submitted>
  <last_update_submitted_qc>February 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>encephalopathy</keyword>
  <keyword>simulated driving</keyword>
  <keyword>sleep disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

